An infusion suite watches the treatment happen. An oral agent is a prescription and a hope.

The RealityThe treatment happens where you cannot see it

⚠️

The Problem

A month of treatment, unobserved.

Adherence assumed from refill timing, and toxicity captured as whatever the patient volunteers at the next visit.

🔧

The Solution

Ask systematically, record in a standard form.

Structured adherence capture and graded side effects, both recorded between visits rather than reconstructed at them.

✅

The Resolution

A trajectory instead of a snapshot.

Problems surfaced while there is still time to act, and a record that shows what actually happened.

Medication adherence: what the evidence actually says

There is a widely quoted range for oral anticancer adherence that we are not going to repeat, because we could not retrieve the source behind it. Here is a figure we did read.

A 2026 meta-analysis in The Oncologist, covering adherence to oral antineoplastic agents, reports cumulative adherence of 84 per cent across 17 studies, 21 cohorts and 7,262 patients, and a lower-bound adherence estimate of 71 per cent across 20 studies, 22 cohorts and 31,230 patients. It summarises the implication as approximately 3 out of 10 patients being at risk of significant undertreatment due to non-adherence.

The population is adults on non-endocrine oral antineoplastics, and the measures include electronic monitoring, medication possession ratio and proportion of days covered. Those measurement methods matter: a possession ratio derived from refill data tells you a prescription was collected, not that it was taken.

Side effect grading, and the version that changed

If side effects are going to be comparable across visits and clinicians, they have to be recorded on a standard scale.

The National Cancer Institute publishes the Common Terminology Criteria for Adverse Events through its Cancer Therapy Evaluation Program. The current version is CTCAE v6.0, published 22 July 2025.

Its five grades are defined as follows. Grade 1 is mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 is moderate; minimal, local or noninvasive intervention indicated; limiting instrumental activities of daily living. Grade 3 is severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4 is life-threatening consequences with urgent intervention indicated. Grade 5 is death related to the adverse event.

Two things changed in version 6. NCI describes development focus areas including grading adverse events in patients with abnormal baseline laboratory values, characterising events associated with immunotherapeutics, and refining categorisation of cardiac-related events. And the grade 2 and grade 3 definitions now carry pediatric-impact language that version 5 did not. Content quoting v5.0 grade wording is a version behind.

Risk evaluation strategies and what they demand of a practice

Some oral agents carry obligations that fall on the prescriber and the dispenser, not only on the manufacturer.

FDA describes a Risk Evaluation and Mitigation Strategy as a drug safety program FDA can require for certain medications with serious safety concerns, to help ensure the benefits outweigh the risks, and notes that only a few medications require one.

Where elements to assure safe use apply, the statute allows requirements that prescribers have particular training or experience or be specially certified, that pharmacies, practitioners or health care settings be specially certified, that the drug be dispensed only in certain settings, that it be dispensed with evidence or documentation of safe-use conditions such as laboratory test results, that each patient be subject to certain monitoring, and that each patient be enrolled in a registry.

Practically that means a prescriber may have to complete training, document counselling, enrol patients and perform monitoring, and a dispensing setting may have to verify that laboratory monitoring has occurred or that a patient or prescriber is enrolled. We are not naming specific drugs here, because each one would need checking on FDA’s own database rather than against a list that ages. What a practice needs is a way to know, at prescribing time, whether the agent in front of them carries such obligations.

Coverage boundaries, and a claim that is usually wrong

This one causes real friction at the front desk and is worth stating precisely.

Medicare’s oral anticancer drug benefit is narrow. A CMS policy article sets four criteria, all of which must be met: the drug is FDA approved; it has the same active ingredients as a non-self-administrable anticancer chemotherapeutic drug or biological covered when furnished incident to a practitioner’s service; it is used for the same anticancer chemotherapeutic indications, including off-label uses; and it is prescribed by a practitioner licensed to prescribe such drugs. If those are not met, the drug is denied as non-covered.

On the other side, 42 CFR 423.100 excludes from the definition of a Part D drug anything for which payment is available under Part A or Part B. So the two are mutually exclusive for a given prescription.

The consequence is that most modern oral oncolytics, which have no injectable equivalent, fall to Part D rather than Part B. “Oral chemotherapy is covered under Part B” is false as a general statement, and a practice that tells a patient otherwise creates a problem for itself. Getting the routing right at prescribing time is a workflow question and belongs with EHR workflow optimization rather than with the billing office after the fact.

Patient-reported outcomes, and what to actually ask

There is a useful federal answer to the question of what to ask patients between visits.

FDA’s October 2024 final guidance on core patient-reported outcomes in cancer clinical trials recommends a core set of five concepts: disease-related symptoms, symptomatic adverse events, an overall side effect impact summary measure, physical function, and role function.

That guidance is written for trials and its recommendations are nonbinding, so we are not suggesting it is a requirement for routine care. What it is, is a considered federal view on which five things carry the most information about how a patient is doing on treatment, arrived at by an agency that reviews this evidence for a living. As a starting specification for what a between-visits check-in should capture, that is a better basis than improvising a questionnaire.

• Do not rely on refill data alone. It measures collection, not consumption.
• Grade side effects on CTCAE v6.0. Version 5 wording is superseded.
• Know at prescribing time whether a REMS applies. The obligation is yours, not only the manufacturer’s.
• Check Part B versus Part D before the patient does. Most oral agents are Part D.

Qventive provides oral oncolytic tracking EHR services in Hackensack NJ, normally within IT support for oncology practices rather than as a standalone project.

Where tracking depends on how the system is configured or on a patient-facing tool, that work runs through oncology EHR and IT support, and every route patient data takes between visits belongs in your HIPAA risk analysis.

Oral oncolytics: common questions